Identification of Calcium Channel-Related Gene P2RX2 for Prognosis and Immune Infiltration in Prostate Cancer

• Published in: Disease markers Vol. 2022; pp. 1 - 23
• Main Authors: Li, Qinyu, Wu, Bili, Daba, Motuma, Gao, Xintao, Chen, Bingliang, Song, Guoda, Zeng, Kai, Miao, Jianping, Yuan, Xianglin, Liu, Jihong, Wang, Zhihua, Liu, Bo
• Format: Journal Article
• Language: English
• Published: Amsterdam Hindawi 30.09.2022; Hindawi Limited
• Subjects: Androgens; Biomarkers; Calcium; Calcium channels; Calcium signalling; Cancer therapies; FDA approval; Gene expression; Genes; Genomes; Genomics; Immune checkpoint; Immune system; Immunotherapy; Infiltration; Medical prognosis; Metastasis; Mutation; Patients; Plasmids; Prognosis; Prostate cancer; Sensitivity analysis; Survival analysis; China
• ISSN: 0278-0240; 1875-8630
• DOI: 10.1155/2022/8058160

Prostate cancer is one of the most common malignancies in men. Calcium signaling is implicated in the progression of prostate cancer and plays a critical role in immune cell function. However, whether specific calcium channel-related genes play a crucial role in the immune cell infiltration levels of prostate cancer requires further research. In this study, we performed an integrated analysis of transcriptional, clinical, and somatic mutation data from The Cancer Genome Atlas database and identified the hub calcium channel-related gene P2RX2 to be associated with the prognosis and immune infiltration of prostate cancer. P2RX2 expression was positively correlated with immune cell infiltration levels and the expression of immune checkpoint genes, and downregulation of P2RX2 led to poor survival in patients with prostate cancer. Furthermore, we validated the molecular and clinical characteristics of P2RX2 by using multiple databases and conducting in-vitro experiments. Additionally, drug sensitivity analysis revealed that patients with low P2RX2 expression were sensitive to docetaxel and Bicalutamide. In conclusion, we revealed an association between calcium channel-related genes and prostate cancer, and identified P2RX2 as a biomarker for early diagnosis, prognosis prediction, and aiding treatment decisions for patients with prostate cancer.